Thelansis

Sorbitol Dehydrogenase (SORD) Deficiency Market Outlook Thelansis’s “Sorbitol Dehydrogenase (SORD) Deficiency Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sorbitol Dehydrogenase (SORD) Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will h...

Sorbitol Dehydrogenase (SORD) Deficiency Market Outlook Thelansis’s “Sorbitol Dehydrogenase (SORD) Deficiency Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sorbitol Dehydrogenase (SORD) Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Sorbitol Dehydrogenase (SORD) Deficiency Overview Sorbitol dehydrogenase deficiency (SORD Deficiency) is a progressive hereditary neuropathy that significantly impacts peripheral nerves and motor neurons, leading to considerable disability, sensory loss, and reduced mobility. Consequently, intracellular sorbitol accumulates, and this molecular alteration has been identified as the unde...

 Sorbitol dehydrogenase deficiency (SORD Deficiency) is a progressive hereditary neuropathy that significantly impacts peripheral nerves and motor neurons, leading to considerable disability, sensory loss, and reduced mobility. Consequently, intracellular sorbitol accumulates, and this molecular alteration has been identified as the underlying cause of the disease in a specific subgroup of patients previously diagnosed with Charcot-Marie-Tooth disease (CMT2) or distal hereditary motor neuropathy (dHMN). A subtype of Charcot-Marie-Tooth disease (CMT) is caused by a mutated SORD gene, which encodes for sorbitol dehydrogenase. The mutated gene results in elevated levels of sorbitol, leading to axonal damage in the peripheral nerves. Individuals with SORD Deficiency experience a progressive form of neuropathy, typically commencing in late adolescence. This condition can substantially impede the individual's quality of life, presenting symptoms such as limb weakness, foot deformities, t...